Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis | NEJM
Patients with relapsed or refractory hematologic cancers have a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapy as a bridge to allogeneic hematopoietic stem-cell transplantation (HSC…